Detalhe da pesquisa
1.
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
J Hepatol
; 73(1): 94-101, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32165251
2.
Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.
Clin Gastroenterol Hepatol
; 18(5): 1170-1178.e6, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31606455
3.
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
N Engl J Med
; 375(7): 631-43, 2016 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-27532829
4.
A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.
Hepatology
; 67(5): 1890-1902, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29023915
5.
Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
Cardiovasc Diabetol
; 14: 12, 2015 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-25645567
6.
PET imaging reveals distinctive roles for different regional adipose tissue depots in systemic glucose metabolism in nonobese humans.
Am J Physiol Endocrinol Metab
; 303(9): E1134-41, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22967498
7.
Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.
BMC Endocr Disord
; 11: 9, 2011 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-21529363
8.
Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis.
JHEP Rep
; 3(1): 100191, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33319187
9.
Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
J Pediatr
; 155(3): 369-73, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19464026
10.
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.
Lancet Gastroenterol Hepatol
; 4(6): 445-453, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30922873
11.
Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis.
Hepatol Commun
; 2(6): 683-692, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29881820
12.
Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
Curr Med Res Opin
; 30(7): 1209-18, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24621255
13.
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years.
Diabetes Metab Syndr Obes
; 6: 31-41, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23358123
14.
Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.
Postgrad Med
; 124(4): 21-32, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22913891
15.
Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
Postgrad Med
; 124(4): 33-40, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22913892
16.
Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
Endocr Pract
; 18(2): 227-37, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22446132
17.
Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
Vasc Health Risk Manag
; 8: 255-64, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22566747
18.
Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.
Diabetes Care
; 32(9): 1577-82, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19502544